Arcus Biosciences Market Cap 2017-2022 | RCUS

Arcus Biosciences market cap history and chart from 2017 to 2022. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Arcus Biosciences market cap as of January 27, 2023 is $1.67B.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.675B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $154.040B 9.40
GSK (GSK) United Kingdom $72.263B 9.00
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.195B 19.11
Ginkgo Bioworks Holdings (DNA) United States $3.764B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Biohaven (BHVN) United States $1.282B 0.00
Emergent Biosolutions (EBS) United States $0.672B 5.28
ADC Therapeutics SA (ADCT) Switzerland $0.388B 0.00
Ambrx Biopharma (AMAM) United States $0.075B 0.00
Enzo Biochem (ENZ) United States $0.069B 0.00
Gelesis Holdings (GLS) United States $0.026B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00